Gold prices steady ahead of Fed decision; weekly weakness noted
In a recent transaction, Julian Baker and Felix Baker, directors at BeiGene , Ltd. (NASDAQ:ONC), sold a significant portion of their holdings in the pharmaceutical company. According to the SEC Form 4 filing, the Bakers disposed of a combined 732,827 American Depositary Shares (ADS) at a price of $260 each, amounting to a total value of approximately $190.5 million. The sale comes as BeiGene’s stock trades near its 52-week high of $287.88, with impressive year-to-date returns of 47% and a market capitalization of $29.7 billion.
The transaction, dated February 28, 2025, reflects the Bakers’ ongoing involvement with BeiGene, a biotechnology firm focused on developing innovative cancer therapies. The company has demonstrated strong operational performance with a gross profit margin of 84% and robust revenue growth of 55% over the last twelve months. Post-transaction, the Bakers continue to hold a substantial number of shares, indicating their ongoing commitment to the company’s future.
The filing also highlights the Bakers’ indirect ownership interests through various partnerships and advisory roles, including Baker Bros. Advisors LP, which serves as the investment adviser to related entities 667, L.P., and Baker Brothers Life Sciences, L.P. Despite the sale, the Bakers maintain significant influence over BeiGene’s strategic direction, underscored by their representation on the company’s board. According to InvestingPro analysis, BeiGene appears overvalued at current levels, with 15 additional key insights available to subscribers.
In other recent news, BeiGene announced fourth-quarter revenues of $1.1 billion, exceeding both company and consensus estimates, largely driven by the strong sales of its cancer drug Brukinsa, which reached $828 million. This performance contributed to a full-year revenue of $3.8 billion, marking a 55% increase year-over-year. The company’s guidance for fiscal year 2025 projects revenues between $4.9 billion and $5.3 billion, indicating continued growth. Analysts from Guggenheim, Citizens JMP, TD Cowen, and Jefferies have all raised their price targets for BeiGene, reflecting confidence in the company’s financial trajectory and product performance. Guggenheim and Citizens JMP both set their targets at $348, while TD Cowen and Jefferies increased theirs to $334 and $308, respectively. The analysts maintained positive ratings, with Guggenheim and TD Cowen recommending a Buy, and Citizens JMP rating the stock as Market Outperform. Additionally, BeiGene received FDA Orphan Drug Designation for sonrotocla, intended for the treatment of myelodysplastic syndromes, further expanding its oncology portfolio. The company also highlighted upcoming data releases and potential accelerated approval filings for its drug pipeline, underscoring its commitment to advancing cancer treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.